Boulle A, Clayden P, Cohen K, Cohen T, Conradie F, Dong K, Geffen N, Grimwood A, Hurtado R, Kenyon C, Lawn S, Maartens G, Meintjes G, Mendelson M, Murray M, Rangaka M, Sanne I, Spencer D, Taljaard J, Variava E, Venter WD, Wilson D.
Sanne I, Orrell C, Fox MP, Conradie F, Ive P, Zeinecker J, Cornell M, Heiberg C, Ingram C, Panchia R, Rassool M, Gonin R, Stevens W, Truter H, Dehlinger M, van der Horst C, Mc Intyre J, Wood R.
The President’s Emergency Plan for AIDS Relief Annual Meeting, The 2006 HIV/AIDS Implementer’s Meeting, June 12-15, 2006, Durban, South Africa, Abstract No 477Ive P, Babatyi M, Patrick M, Ian S.
Successful Implementation of Antiretroviral Therapy in a Large Urban Clinic in South Africa. Lisgaris, Ian M Sanne, Pedro Cahn, Alan Landay, Steven Schnittman, Thomas Kelleher, Benigno, Rodriguez.
Abstact submitted to the XIV International AIDS Conference, Barcelona, July 7 – 12 2002., P Piliero, R Koup, S Green, S Schnittman .
TREC T cell levels are inversely related to HIV replication and are selectively and rapidly released into circulation with antiretroviral treatment.
Tuberculosis-associated, IRIS results in modulation of the Innate. SM Eng, I Sanne, S Badal-Faesen, R Wood, N Rajicic and R Tressler. PMID:18228554Sanne I, Strydom G, Barker C, Engelbrecht A.
Immune Compartment in the Absence of Generalized T Cell Activation.16Ruxrungthan K, Pedro RJ, Latiff GH, Conradie F, Domingo P, Lupo S, Pumpradit W, Vingerhoets JH, Peeters M, Peeters I, Kakuda TN, De Smedt G, Woodfall B. Impact of reverse transcriptase resistance on the efficacy of TMC 125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients. Prevalence of CCR-5 Tropic HIV-1 Among Treatment-Experienced Individuals in South Africa Infected with Clade C Virus. Large-scale affordable Pan Leucogated CD4 testing with proactive internal and external quality assessment: in support of the South African national comprehensive care, treatment and management programme for HIV and AIDS. Direct AIDS Intervention™ a Public Private Partnership for the Employed Sector in South Africa.At the intersection of clinical care, and clinical trials, Ian Sanne will offer his expertise from his experience as the founding Director and Chief Executive Officer of Right to Care, a large PEPFAR and Global Fund supported non-profit organization. In Combination With A Fixed Background Regimen Consisting Of Abacavir And Lamivudine In Antiretroviral-Naïve HIV-1 Infected Subjects A phase III Multicentre, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial To Study The Safety And Efficacy Of Once Daily Raltegravir (MK0518) Versus Twice Daily Raltegravir, Each In Combination With Truvada International Trial of Modified Directly Observed Therapy versus Self-Administered Therapy for Participants with First Virologic Failure on a Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Regimen A phase 2b multicentre, randomized, double-blind, comparative trial of UK-453,061, in combination with Tenofovir DF and Emtricitabine versus Efavirenz in combination with Tenofovir DF and Emtricitabine for the treatment of antiretroviral-naïve HIV-1 infected subjects.Ian Sanne has served in a number of leadership roles, both in research and implementation of clinical treatment services. A Phase 2b Multicenter, Randomized, Comparative Trial Of Uk‑453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleotide/Nucleoside Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced Hiv‑1 Infected Subjects With Evidence Of Nnrti Resistant Hiv‑1A randomized placebo-controlled double blind trial comparing two treatment shortening regimens with the standard regimen (two months ethambutol, isoniazid, rifampicin and pyrazinamide followed by four months isoniazid and rifampicin) namely 1) two months moxifloxacin, isoniazid, rifampicin and pyrazinamide followed by two months moxifloxacin, isoniazid and rifampicin and 2) two months ethambutol, moxifloxacin, rifampicin and pyrazinamide followed by two months moxifloxacin and rifampicin for the treatment of adults with pulmonary tuberculosis.Abstact submitted to the XIV International AIDS Conference, Barcelona, July 7 – 12 2002., C van der Horst, A Shaw, J Hinkle, J B Quinn, C Moxham, F Rousseau.Two randomized, controlled, equivalence trials of emtricitabine (FTC) to lamivudine (3TC).Ian Sanne is a native South African and HIV clinician/researcher and is the International Vice-Chair of the AIDS Clinical Trials Group.